Terms: = Ovarian cancer AND ALDH2, ALDHI, 217, ENSG00000111275, ALDH-E2, P05091, MGC1806, ALDM AND Prognosis
24 results:
1. Breast density reduction as a predictor for prognosis in premenopausal women with estrogen receptor-positive breast cancer: an exploratory analysis of the updated ASTRRA study.
Bae SJ; Kim HJ; Kim HA; Ryu JM; Park S; Lee EG; Im SA; Jung Y; Park MH; Park KH; Kang SH; Park E; Kim SY; Lee MH; Kim LS; Lee A; Noh WC; Gwark S; Kim S; Jeong J
Int J Surg; 2024 Feb; 110(2):934-942. PubMed ID: 38000057
[TBL] [Abstract] [Full Text] [Related]
2. Searching for prognostic markers for Stage I epithelial ovarian cancer: A role for systemic inflammatory markers.
Borella F; Bertero L; Valabrega G; Fucina S; Cassoni P; Benedetto C
Int J Gynaecol Obstet; 2024 Jan; 164(1):262-269. PubMed ID: 37496460
[TBL] [Abstract] [Full Text] [Related]
3. Radiotherapy in recurrent ovarian cancer: updated results of involved-field radiation therapy.
Lee BM; Lee SJ; Kim N; Byun HK; Kim YB
Int J Gynecol Cancer; 2023 Jul; 33(7):1106-1111. PubMed ID: 37217239
[TBL] [Abstract] [Full Text] [Related]
4. LILRB1
Xu X; Yin S; Wang Y; Zhu Q; Zheng G; Lu Y; Li T; Zhu C
Int Immunopharmacol; 2023 Jun; 119():110162. PubMed ID: 37075669
[TBL] [Abstract] [Full Text] [Related]
5. PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers.
Alwosaibai K; Aalmri S; Mashhour M; Ghandorah S; Alshangiti A; Azam F; Selwi W; Gharaibeh L; Alatawi Y; Alruwaii Z; Alsaab HO
BMC Cancer; 2023 Jan; 23(1):13. PubMed ID: 36604635
[TBL] [Abstract] [Full Text] [Related]
6. Comparison of survival outcomes and effects of therapy between subtypes of high-grade endometrial cancer - a population-based study.
Scharl S; Gerken M; Sprötge T; Kronberger K; Scharl A; Ignatov A; Ortmann O; Kölbl O; Klinkhammer-Schalke M; Papathemelis T
Acta Oncol; 2021 Jul; 60(7):897-903. PubMed ID: 33905297
[TBL] [Abstract] [Full Text] [Related]
7. The levels of soluble cMET ectodomain in the blood of patients with ovarian cancer are an independent prognostic biomarker.
Klotz DM; Link T; Goeckenjan M; Wimberger P; Kuhlmann JD
Mol Oncol; 2021 Sep; 15(9):2491-2503. PubMed ID: 33690968
[TBL] [Abstract] [Full Text] [Related]
8. Management and clinical outcomes of patients with recurrent/progressive ovarian clear cell carcinoma.
Huang HJ; Yang LY; Tung HJ; Ku FC; Wu RC; Tang YH; Chang WY; Jung SM; Wang CC; Lin CT; Liu FY; Lin G; Chen MY; Chou HH; Chang TC; Chao A; Lai CH
J Formos Med Assoc; 2020 Apr; 119(4):793-804. PubMed ID: 31818713
[TBL] [Abstract] [Full Text] [Related]
9. MiR-217 Inhibits M2-Like Macrophage Polarization by Suppressing Secretion of Interleukin-6 in ovarian cancer.
Jiang B; Zhu SJ; Xiao SS; Xue M
Inflammation; 2019 Oct; 42(5):1517-1529. PubMed ID: 31049770
[TBL] [Abstract] [Full Text] [Related]
10. Serum Human Epididymis Secretory Protein 4 (HE4) is a Potential Prognostic Biomarker in Non-Small Cell Lung cancer.
Mo D; He F
Clin Lab; 2018 Sep; 64(9):1421-1428. PubMed ID: 30274019
[TBL] [Abstract] [Full Text] [Related]
11. Secondary tumors of the GI tract: origin, histology, and endoscopic findings.
Gilg MM; Gröchenig HP; Schlemmer A; Eherer A; Högenauer C; Langner C
Gastrointest Endosc; 2018 Jul; 88(1):151-158.e1. PubMed ID: 29476848
[TBL] [Abstract] [Full Text] [Related]
12. Paediatric dysgerminoma: Results of three consecutive French germ cell tumours clinical studies (TGM-85/90/95) with late effects study.
Duhil de Bénazé G; Pacquement H; Faure-Conter C; Patte C; Orbach D; Corradini N; Berger C; Sudour-Bonnange H; Vérité C; Martelli H; Fresneau B
Eur J Cancer; 2018 Mar; 91():30-37. PubMed ID: 29331749
[TBL] [Abstract] [Full Text] [Related]
13. Elevated plasma fibrinogen levels and prognosis of epithelial ovarian cancer: a cohort study and meta-analysis.
Luo Y; Kim HS; Kim M; Lee M; Song YS
J Gynecol Oncol; 2017 May; 28(3):e36. PubMed ID: 28382799
[TBL] [Abstract] [Full Text] [Related]
14. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.
Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA
Hum Reprod; 2017 May; 32(5):1033-1045. PubMed ID: 28333356
[TBL] [Abstract] [Full Text] [Related]
15. Expression Patterns of Nrf2 and Keap1 in ovarian cancer Cells and their Prognostic Role in Disease Recurrence and Patient Survival.
Cho HY; Kim K; Kim YB; Kim H; No JH
Int J Gynecol Cancer; 2017 Mar; 27(3):412-419. PubMed ID: 28129239
[TBL] [Abstract] [Full Text] [Related]
16. MMP-14 and CD44 in Epithelial-to-Mesenchymal Transition (EMT) in ovarian cancer.
Vos MC; Hollemans E; Ezendam N; Feijen H; Boll D; Pijlman B; van der Putten H; Klinkhamer P; van Kuppevelt TH; van der Wurff AA; Massuger LF
J Ovarian Res; 2016 Sep; 9(1):53. PubMed ID: 27590006
[TBL] [Abstract] [Full Text] [Related]
17. Chromosome 20q13.2 ZNF217 locus amplification correlates with decreased E-cadherin expression in ovarian clear cell carcinoma with PI3K-Akt pathway alterations.
Huang HN; Huang WC; Lin CH; Chiang YC; Huang HY; Kuo KT
Hum Pathol; 2014 Nov; 45(11):2318-25. PubMed ID: 25281027
[TBL] [Abstract] [Full Text] [Related]
18. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
[TBL] [Abstract] [Full Text] [Related]
19. Amplification of zinc finger gene 217 (ZNF217) and cancer: when good fingers go bad.
Quinlan KG; Verger A; Yaswen P; Crossley M
Biochim Biophys Acta; 2007 Jun; 1775(2):333-40. PubMed ID: 17572303
[TBL] [Abstract] [Full Text] [Related]
20. Large-scale proteomics analysis of human ovarian cancer for biomarkers.
Bengtsson S; Krogh M; Szigyarto CA; Uhlen M; Schedvins K; Silfverswärd C; Linder S; Auer G; Alaiya A; James P
J Proteome Res; 2007 Apr; 6(4):1440-50. PubMed ID: 17315909
[TBL] [Abstract] [Full Text] [Related]
[Next]
